Chemotherapy or tyrosine kinase inhibitor for second line treatment in advanced non small cell lung cancer

被引：0
|
作者：
Jyoti, B. [1 ]
McKay, M. [1 ]
Wong, H. [1 ]
Alam, F. [1 ]
Eswar, C. [1 ]
Jain, P. [1 ]
Littler, J. A. H. [1 ]
Maguire, J. [1 ]
Schofield, C. P. [1 ]
Siva, A. [1 ]
Ramani, V. S. [1 ]
机构：
[1] Clatterbridge Ctr Oncol, Wirral, Merseyside, England
来源：
LUNG CANCER | 2012年 / 75卷
关键词：
D O I：
10.1016/S0169-5002(12)70019-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
18
引用
收藏
页码：S6 / S6
页数：1
相关论文
共 50 条
  • [31] Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations
    Xu, Jianlin
    Zhang, Xueyan
    Yang, Haitang
    Ding, Guozheng
    Jin, Bo
    Lou, Yuqing
    Zhang, Yanwei
    Wang, Huimin
    Han, Baohui
    ONCOTARGET, 2016, 7 (42) : 68442 - 68448
  • [32] Ceritinib: A New Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer
    Cooper, Maryann R.
    Chim, Helen
    Chan, Hoyi
    Durand, Cheryl
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (01) : 107 - 112
  • [33] EGFR TYROSINE KINASE INHIBITOR USED IN NON-SMALL CELL LUNG CANCER
    Joshi, Pooja
    Singh, Anita
    Bisht, Dheeraj
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (03): : 1033 - 1041
  • [34] EGFR Tyrosine Kinase Inhibitor and Chemotherapy in EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Nishino, Kazumi
    Kimura, Madoka
    Inoue, Takako
    Uchida, Junji
    Kumagai, Toru
    Imamura, Fumio
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S526 - S526
  • [35] Outcomes of Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in One Institution
    Lee, Seok Jeong
    Kang, Hyun Ju
    Kim, Seo Woo
    Ryu, Yon Ju
    Lee, Jin Hwa
    Kim, Yookyung
    Chang, Jung Hyun
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2014, 77 (01) : 13 - 17
  • [36] Efficacy of second-line chemotherapy after immunotherapy in advanced non-small cell lung cancer
    Hirata, Tsuyoshi
    Hakozaki, Taiki
    JOURNAL OF THORACIC DISEASE, 2023, 15 (07) : 3554 - 3556
  • [37] FREQUENCY OF SECOND-LINE CHEMOTHERAPY FOR ELDERLY PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Suzuki, Kensuke
    Kenmotsu, Hirotsugu
    Taira, Tetsuhiko
    Naito, Tateaki
    Kimura, Madoka
    Hisamatsu, Yasushi
    Tokito, Takaaki
    Imai, Hisao
    Akamatsu, Hiroaki
    Ono, Akira
    Shukuya, Takehito
    Murakami, Haruyasu
    Takahashi, Toshiaki
    Endo, Masahiro
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S484 - S484
  • [38] Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer
    Tan, Fenlai
    Shi, Yuankai
    Wang, Yinxiang
    Ding, Lieming
    Yuan, Xiaobin
    Sun, Yan
    FUTURE ONCOLOGY, 2015, 11 (03) : 385 - 397
  • [39] Tyrosine kinase inhibitor conjugated quantum dots for non-small cell lung cancer (NSCLC) treatment
    Kulkarni, Nishant S.
    Parvathaneni, Vineela
    Shukla, Snehal K.
    Barasa, Leonard
    Perron, Jeanette C.
    Yoganathan, Sabesan
    Muth, Aaron
    Gupta, Vivek
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 133 : 145 - 159
  • [40] EGFR tyrosine kinase inhibitor in advanced non-small cell lung cancer with wild-type EGFR
    Wang, Z.
    Wu, Y. L.
    Yang, J.
    Wang, B.
    Huang, Y.
    Zhou, Q.
    Xu, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345